ScreenPoint Medical’s Transpara AI has analyzed 5 million mammograms and 1 million Tomosynthesis studies, spotlighting at RSNA 2023. Studies reveal its role as a ‘second pair’ of eyes aiding cancer detection, and reducing recall rates. Published research highlights its superiority in short-term risk assessment. CEO Mark Koeniguer emphasizes Transpara’s consistent performance, benefitting diverse demographics globally. With FDA and CE Mark approvals, it’s used in 30+ countries, potentially spotting 45% more interval cancers earlier. Transpara reshapes breast health care, supporting radiologists and enhancing workflow efficiency.
ScreenPoint Medical has achieved a significant milestone with its Transpara breast AI, surpassing the analysis of 5 million mammograms, inclusive of over 1 million Tomosynthesis (3D) exams, aimed at aiding radiologists in interpreting mammography studies. This notable achievement will be spotlighted at the prestigious 109th Annual Radiological Society of North America (RSNA) meeting, scheduled from November 26th to 30th, 2023, at McCormick Place in Chicago, IL.
The announcement regarding Transpara’s milestone underscores its pivotal role as a supplementary tool for radiologists, acting as a ‘second pair’ of eyes to aid in the early detection of cancers and reducing recall rates. With a global presence in hundreds of sites, Transpara has established itself as the benchmark for Breast AI, seamlessly integrating into the workflow of radiology reading environments, whether in single-reading or double-reading settings, and supporting various major mammography gantry manufacturers.
ScreenPoint Medical is geared up to showcase Transpara’s advancements at RSNA 2023, occupying South Hall #3947 at McCormick Place in Chicago, IL, during the Scientific Assembly and Annual Meeting from November 26th to 30th, 2023.
The impact of Transpara on the mammography screening process has been the focal point of multiple significant research studies published in top-tier peer-reviewed publications throughout the year. Among these studies is a recent article published in Radiology (Lauritzen, et al) in August 2023. This publication, titled “Assessing Breast Cancer Risk by Combining AI for Lesion Detection and Mammographic Texture,” showcased Transpara’s collaboration with two other measures, demonstrating a superior short-term risk assessment compared to prevalent models like Gail and TC8.
Mark Koeniguer, CEO of ScreenPoint Medical, expressed pride in Transpara’s extensive utilization in clinical settings, analyzing 5 million mammograms and 1 million tomosynthesis exams. “We are immensely proud that numerous studies consistently highlight the value Transpara brings to both breast health care providers and patients,” stated Koeniguer. He emphasized Transpara’s consistent performance across diverse demographics and patient profiles, stressing its potential to aid radiologists in early cancer detection and workload reduction. Koeniguer also highlighted the ongoing development efforts aimed at broadening the scope and impact of the Transpara Portfolio.
Transpara holds FDA clearance and European regulatory approval (CE Mark) for utilization with 2D and 3D mammography across multiple manufacturers. Implemented in hundreds of leading centers across over 30 countries, Transpara is designed to complement radiologists’ expertise. Research indicates that Transpara can potentially identify up to 45% of interval cancers earlier while streamlining workflow and alleviating workload pressures on radiologists.
Overall, ScreenPoint Medical’s Transpara AI marks a milestone with 5 million mammograms and 1 million Tomosynthesis studies, showcased at RSNA 2023. Demonstrating as a valuable ‘second pair’ of eyes for radiologists, Transpara aids in early cancer detection and minimizes recalls. Published studies validate its superior risk assessment abilities. CEO Mark Koeniguer emphasizes Transpara’s consistent global impact and ongoing enhancements. With FDA and CE Mark approvals, Transpara operates globally, potentially identifying 45% more interval cancers earlier. It transforms radiology, supporting professionals, and enhancing workflow efficiency.
